CN109985036A - 蛇床子素的新用途及其应用 - Google Patents

蛇床子素的新用途及其应用 Download PDF

Info

Publication number
CN109985036A
CN109985036A CN201810607835.1A CN201810607835A CN109985036A CN 109985036 A CN109985036 A CN 109985036A CN 201810607835 A CN201810607835 A CN 201810607835A CN 109985036 A CN109985036 A CN 109985036A
Authority
CN
China
Prior art keywords
osthole
ophthalmology
disease
fibrosis
new application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810607835.1A
Other languages
English (en)
Inventor
郭涛
范先群
范宇晨
郭丽
彭玉豪
魏嘉洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ninth Peoples Hospital Shanghai Jiaotong University School of Medicine
Original Assignee
Ninth Peoples Hospital Shanghai Jiaotong University School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ninth Peoples Hospital Shanghai Jiaotong University School of Medicine filed Critical Ninth Peoples Hospital Shanghai Jiaotong University School of Medicine
Priority to CN201810607835.1A priority Critical patent/CN109985036A/zh
Publication of CN109985036A publication Critical patent/CN109985036A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及医药技术领域。蛇床子素的新用途，其特征在于：蛇床子素可在眼科疾病的发生、发展中抑制相关细胞的纤维化，用于治疗患者的眼科疾病。蛇床子素为眼科相关的纤维化疾病提供新的治疗思路。

Description

蛇床子素的新用途及其应用
技术领域
本发明涉及医药技术领域领域，具体涉及蛇床子素。
背景技术
蛇床子素为黄绿色粉末,高含量为白色针状结晶粉末。蛇床子素具有解痉、降血压、抗心律失常、增强免疫功能及广谱抗菌作用。温肾壮阳，燥湿，祛风，杀虫。用于阳痿、宫冷、不孕、寒湿带下、湿鼻腰痛；外治外阴湿疹，妇人阴痒，滴虫性阴道炎。未见蛇床子素用于治疗眼科疾病的任何报道。
发明内容
本发明的目的在于，提供一种蛇床子素的新用途，解决以上至少一个技术问题。
本发明所解决的技术问题可以采用以下技术方案来实现：
蛇床子素的新用途，其特征在于：蛇床子素可在眼科疾病的发生、发展中抑制相关细胞的纤维化，用于治疗患者的眼科疾病。
蛇床子素为眼科相关的纤维化疾病提供新的治疗思路。
所述蛇床子素用于治疗小梁网组织纤维化、小梁网切除术后的瘢痕化、结膜瘢痕化、假性上睑下垂、眼部纤维化疾病、眼部皮肤瘢痕等眼科疾病。
所述蛇床子素被制成片剂、胶囊、丸剂、口服液、针剂、眼药水、眼药膏、外用药膏等药物的形式。蛇床子素经口服，针剂注入、或者直接滴入眼睛，均可以抑制相关细胞纤维化。药物中还可以添加辅料。
附图说明
图1为本发明不同实验组的FN的表达水平的条状图；
图2为本发明不同实验组的Col-IV的表达水平的条状图；
图3为本发明不同实验组的LN的表达水平的条状图。
具体实施方式
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解，下面结合具体图示进一步阐述本发明。
实验方法：
①细胞铺板：人正常小梁网细胞(Normal Trabecular Meshwork Cells，NTM)用含10％胎牛血清(FBS)的F12培养，待生长状态良好的人正常小梁网细胞融合至75％-80％时，将细胞用胰酶消化，铺种到6孔板内加2ml培养液。
②实验分组：将人正常小梁网细胞正常培养作为空白对照组，将人正常小梁网细胞加入地塞米松作为标准组，将人正常小梁网细胞加入地塞米松和不同浓度蛇床子素作为实验组(标准组和实验组培养液中地塞米松浓度均为10-7mol/l，蛇床子素浓度分别为1，3，10，30，100μmol/l)，培养小梁网细胞至第0，3，6，12，24，48h。地塞米松可诱导细胞中转化生长因子β(TGFβ)，纤维连接蛋白(FN)，IV型胶原(COL-IV)，层粘连蛋白(LN)等表达量升高红，引起细胞纤维化。
③小梁网细胞外基质蛋白基因和蛋白分泌检测：设计层粘连蛋白(LN)、IV型胶原蛋白(Col-IV)和纤维连接蛋白(FN)基因的引物序列，RT-PCR检测LN、COL-IV、FN的信使RNA表达；利用Anti-LN、Anti-Col-IV、Anti-FN抗体，Western-Blot检测小梁网细胞外基质蛋白表达水平。
实验数据见图1、2、3。
实验结论：蛇床子素干预后，TGFβ，FN，COL-IV，LN表达含量降低。说明蛇床子素可在眼科疾病的发生、发展中抑制相关细胞的纤维化，用于治疗患者的眼科疾病。蛇床子素为眼科相关的纤维化疾病提供新的治疗思路。
所述蛇床子素可用于治疗小梁网组织纤维化、小梁网切除术后的瘢痕化、结膜瘢痕化、假性上睑下垂、眼部纤维化疾病、眼部皮肤瘢痕等眼科疾病。
所述蛇床子素可被制成片剂、胶囊、丸剂、口服液、针剂、眼药水、眼药膏、外用药膏等药物的形式。蛇床子素经口服，针剂注入、或者直接滴入眼睛，均可以抑制相关细胞纤维化。药物中还可以添加辅料。
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。

Claims (3)

1.蛇床子素的新用途，其特征在于：蛇床子素可在眼科疾病的发生、发展中抑制相关细胞的纤维化，用于治疗患者的眼科疾病。
2.根据权利要求1所述的蛇床子素的新用途，其特征在于：所述蛇床子素用于治疗小梁网组织纤维化、小梁网切除术后的瘢痕化、结膜瘢痕化、假性上睑下垂、眼部纤维化疾病、眼部皮肤瘢痕。
3.根据权利要求1所述的蛇床子素的新用途，其特征在于：所述蛇床子素被制成片剂、胶囊、丸剂、口服液、针剂、眼药水、眼药膏、外用药膏。
CN201810607835.1A 2018-06-13 2018-06-13 蛇床子素的新用途及其应用 Pending CN109985036A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810607835.1A CN109985036A (zh) 2018-06-13 2018-06-13 蛇床子素的新用途及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810607835.1A CN109985036A (zh) 2018-06-13 2018-06-13 蛇床子素的新用途及其应用

Publications (1)

Publication Number Publication Date
CN109985036A true CN109985036A (zh) 2019-07-09

Family

ID=67128703

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810607835.1A Pending CN109985036A (zh) 2018-06-13 2018-06-13 蛇床子素的新用途及其应用

Country Status (1)

Country Link
CN (1) CN109985036A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101121706A (zh) * 2007-09-18 2008-02-13 南京中瑞药业有限公司 一种香豆素衍生物及其制备方法和用途
WO2010009091A2 (en) * 2008-07-14 2010-01-21 Herbalscience Group, Llc Anti-inflammatory and anti-allergy extracts from nettle
CN101647796A (zh) * 2009-08-11 2010-02-17 华东师范大学 蛇床子素在制备抑制血管新生药物中的应用
CN101780071A (zh) * 2010-03-30 2010-07-21 苏州大学 蛇床子素在制备防治心肌纤维化药物中的应用
US20150297560A1 (en) * 2014-04-22 2015-10-22 National Defense Medical Center Use of osthole for treating focal segmental glomerulosclerosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101121706A (zh) * 2007-09-18 2008-02-13 南京中瑞药业有限公司 一种香豆素衍生物及其制备方法和用途
WO2010009091A2 (en) * 2008-07-14 2010-01-21 Herbalscience Group, Llc Anti-inflammatory and anti-allergy extracts from nettle
CN101647796A (zh) * 2009-08-11 2010-02-17 华东师范大学 蛇床子素在制备抑制血管新生药物中的应用
CN101780071A (zh) * 2010-03-30 2010-07-21 苏州大学 蛇床子素在制备防治心肌纤维化药物中的应用
US20150297560A1 (en) * 2014-04-22 2015-10-22 National Defense Medical Center Use of osthole for treating focal segmental glomerulosclerosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAISY Y. SHU等: ""Myofibroblast transdifferentiation: the dark force in ocular wound healing and fibrosis"", 《PROG RETIN EYE RES.》 *
侯晓华等: ""蛇床子素干预人增生性瘢痕成纤维细胞增殖及转化生长因子β1的表达"", 《中国组织工程研究与临床康复》 *
郑立卿等: ""蛇床子素药理作用研究进展"", 《神经药理学报》 *

Similar Documents

Publication Publication Date Title
McBrien et al. Role of the sclera in the development and pathological complications of myopia
TWI720984B (zh) 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
WO2018171410A1 (zh) 一种融合蛋白及其制备方法和其应用
Zhang et al. Metformin protects chondrocytes against IL-1β induced injury by regulation of the AMPK/NF-κ B signaling pathway
Uy et al. Stem cell therapy: a novel approach for vision restoration in retinitis pigmentosa
EP3604342B1 (en) Fusion protein, preparation method therefor and application thereof in preparing ophthalmic disease treatment, anti-inflammation and anti-tumor medicament
CN109985036A (zh) 蛇床子素的新用途及其应用
Shi et al. Neuroprotective role of dexmedetomidine pretreatment in cerebral ischemia injury via ADRA2A‑mediated phosphorylation of ERK1/2 in adult rats
CN102625707A (zh) Hip/pap或其衍生物的新应用
Azzam et al. Anatomy, head and neck, eye ophthalmic vein
KR20180050744A (ko) 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
Shimada et al. Type I collagen accelerates the spreading of lens epithelial cells through the expression and activation of matrix metalloproteinases
CN108186659A (zh) 黄芪甲苷在制备治疗及延缓椎间盘退行性变药物中的应用
Teplitsky et al. ALK5 inhibition of subconjunctival scarring from glaucoma surgery: effects of SB-431542 compared to mitomycin C in human tenon's capsule fibroblasts
CN103443276B (zh) 用于愈合或治疗伤口的分子靶标
Wong et al. Applications, and efficient large-scale production, of recombinant human epidermal growth factor
Wang et al. Ripasudil in a model of pigmentary glaucoma
CN114053419B (zh) 去甲肾上腺素或β-肾上腺素能受体抑制剂在制备治疗糖尿病神经修复的药物中的应用
Toda et al. The different binding properties of cultured human corneal endothelial cell subpopulations to Descemet's membrane components
Guo et al. Effect of IL-1β on apoptosis of synovial cells in rheumatoid arthritis rats via the NF-κB pathway.
KR20140097584A (ko) 의약 조성물 및 이를 이용한 약용 화장품
CN102533653A (zh) MSCs、ASCs诱导的5-HT神经细胞及其微囊化制备方法与应用
CN106913861B (zh) Ctcf陷阱蛋白在制备抗葡萄膜黑色素瘤药物中的应用
CN110585196B (zh) 一种治疗及预防眼科疾病的药物及其应用
CN101932313A (zh) Hedgehog激动剂在治疗肌骨骼相关障碍中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190709

WD01 Invention patent application deemed withdrawn after publication